Opinion|Videos|October 8, 2024
Overview of DAPA ECHO Trial
Author(s)Javed Butler, MD, MPH, MBA
Key Takeaways
- The DAPA ECHO trial focused on dapagliflozin's effects on myocardial performance in nondiabetic heart failure patients.
- A randomized, double-blind, placebo-controlled design was employed, using echocardiography to assess cardiac function.
Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients with nondiabetic heart failure, including the study’s objective, design, methodology, results, and key clinical implications for the use of dapagliflozin in this population.
Advertisement
Video content above is prompted by the following:
- Discuss the data presented at European Society of Cardiology Congress 2024 for the DAPA ECHO trial in which the effects of dapagliflozin on myocardial performance were studied in patients with nondiabetic heart failure.
- What was the objective of this analysis?
- How was this study designed, and what methodology was used?
- What results were presented?
- Provide your key takeaways from this study. What are the key clinical implications in using dapagliflozin in patients with nondiabetic heart failure?
Advertisement
Related to this article
Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.
In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.
From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.
The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.
New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.
In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5